DE3773089D1 - Verfahren zur herstellung von thiazolidinedion-derivaten. - Google Patents

Verfahren zur herstellung von thiazolidinedion-derivaten.

Info

Publication number
DE3773089D1
DE3773089D1 DE8787306425T DE3773089T DE3773089D1 DE 3773089 D1 DE3773089 D1 DE 3773089D1 DE 8787306425 T DE8787306425 T DE 8787306425T DE 3773089 T DE3773089 T DE 3773089T DE 3773089 D1 DE3773089 D1 DE 3773089D1
Authority
DE
Germany
Prior art keywords
compound
chem
formula
given above
meaning given
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787306425T
Other languages
English (en)
Inventor
Kanji Meguro
Takeshi Fujita
Chitoshi Hatanaka
Satoru Ooi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE3773089D1 publication Critical patent/DE3773089D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE8787306425T 1986-07-24 1987-07-20 Verfahren zur herstellung von thiazolidinedion-derivaten. Expired - Lifetime DE3773089D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17427886 1986-07-24

Publications (1)

Publication Number Publication Date
DE3773089D1 true DE3773089D1 (de) 1991-10-24

Family

ID=15975864

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787306425T Expired - Lifetime DE3773089D1 (de) 1986-07-24 1987-07-20 Verfahren zur herstellung von thiazolidinedion-derivaten.

Country Status (9)

Country Link
US (3) US4812570A (de)
EP (1) EP0257781B1 (de)
JP (1) JP2611244B2 (de)
KR (1) KR950008312B1 (de)
AT (1) ATE67497T1 (de)
DE (1) DE3773089D1 (de)
ES (1) ES2037718T3 (de)
GR (1) GR3003381T3 (de)
HU (1) HU198043B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203330B (en) * 1987-06-10 1991-07-29 Pfizer Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
US4956374A (en) * 1988-07-29 1990-09-11 Bristol-Myers Company Polysubstituted thiazolylpyridine carboxyamide antifungal antibiotic
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
EP0839812A1 (de) * 1990-04-27 1998-05-06 Sankyo Company Limited Herstellung von Benzylthiazolidinederivaten
DE69202715T2 (de) * 1991-03-25 1995-11-23 Takeda Chemical Industries Ltd Verfahren zur Herstellung von Ethern.
JP2687811B2 (ja) * 1991-03-25 1997-12-08 武田薬品工業株式会社 エーテル類の製造法
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585495A (en) * 1991-12-20 1996-12-17 The Upjohn Company Reduction method for substituted 5-methylene-thiazolidinediones
AU4104593A (en) * 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
KR20080011356A (ko) 1997-06-18 2008-02-01 스미스클라인비이참피이엘시이 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9723295D0 (en) 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
NZ511614A (en) * 1998-11-12 2003-12-19 Smithkline Beecham P Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
JP2003507473A (ja) * 1999-07-01 2003-02-25 ジェロン コーポレイション テロメラーゼインヒビターおよびその使用の方法
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
FR2820742B1 (fr) * 2001-02-14 2005-03-11 Ppg Sipsy Procede de preparation de composes derives de thiazolidinedione, d'oxazolidinedione ou d'hydantoine
FR2820741A1 (fr) * 2001-02-14 2002-08-16 Ppg Sipsy Procede de preparation de composes derives de thiazolidinedione, d'oxazolidinedione ou d'hydantoine
CA2470075A1 (en) * 2001-12-20 2003-07-03 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
WO2004000810A1 (en) * 2002-06-19 2003-12-31 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. A process for the production of substituted phenyl ethers
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004066952A2 (en) * 2003-01-29 2004-08-12 Incyte Corporation Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
HUP0304096A2 (hu) * 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
WO2005080387A2 (en) 2004-02-20 2005-09-01 Synthon B.V. Processes for making pioglitazone and compounds of the processes
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2008128126A1 (en) 2007-04-11 2008-10-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008142706A2 (en) * 2007-05-18 2008-11-27 Matrix Laboratories Ltd Novel process for the synthesis of pioglitazone and its salts thereof
JP2009023572A (ja) * 2007-07-23 2009-02-05 Hitachi Ltd 移動車両
US20090118514A1 (en) * 2007-11-06 2009-05-07 Raghupathi Reddy Anumula Processes for preparing pioglitazone and its pharmaceutically acceptable salts
CN102348457A (zh) 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
EP2526424A2 (de) 2010-01-22 2012-11-28 Dana-Farber Cancer Institute, Inc. Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, prävention und therapie von stoffwechselerkrankungen
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2012153312A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Process for the purification of pioglitazone
JP2013241361A (ja) * 2012-05-21 2013-12-05 Tokuyama Corp ５−ベンジル−２，４−チアゾリジンジオン誘導体の製造方法
ES2668310T3 (es) 2012-11-05 2018-05-17 Commissariat à l'énergie atomique et aux énergies alternatives Combinación de un agente anticanceroso tal como un inhibidor de la tirosina cinasa y un antagonista STAT5, preferiblemente una tiazolidindiona, para eliminar las células madre de cáncer hematológico in vivo y para prevenir la recidiva de cáncer hematológico
JP6060916B2 (ja) 2014-02-12 2017-01-18 マツダ株式会社 自動車の前部整流構造
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales

Also Published As

Publication number Publication date
KR950008312B1 (ko) 1995-07-27
USRE36575E (en) 2000-02-15
EP0257781A1 (de) 1988-03-02
ATE67497T1 (de) 1991-10-15
US4898947A (en) 1990-02-06
HUT47571A (en) 1989-03-28
HU198043B (en) 1989-07-28
KR880001647A (ko) 1988-04-25
ES2037718T3 (es) 1993-07-01
EP0257781B1 (de) 1991-09-18
GR3003381T3 (en) 1993-02-17
JPS63139182A (ja) 1988-06-10
JP2611244B2 (ja) 1997-05-21
US4812570A (en) 1989-03-14

Similar Documents

Publication Publication Date Title
DE3773089D1 (de) Verfahren zur herstellung von thiazolidinedion-derivaten.
KR870003086A (ko) 설포닐우레아 유도체의 제조방법
ATE10939T1 (de) Verwendung von 1,3-dioxolen-2-on-derivaten.
KR870002056A (ko) 치환된 프로파르길옥시아세토니트릴 유도체의 제조 방법
KR830007686A (ko) 세팔로 스포린 유도체의 제조방법
ATE210136T1 (de) Verfahren zur herstellung von alkylhydrogenchlorsilanen
DE68900323D1 (de) Verfahren zur herstellung von alkylpyruvaten.
ATE115567T1 (de) Verfahren zur herstellung von halogensulfonyl- substituierten pyridinen.
DE3769730D1 (de) Verfahren zur herstellung von isothiazolonen.
KR850002979A (ko) 1,2,3-트리티안화합물의 신규 제조방법
ATE138376T1 (de) Verfahren zur herstellung von benzylphthalazinonderivaten und von deren salzen
ATE60319T1 (de) Verfahren zur herstellung von tetrafluorphthalsaeure.
ATE165824T1 (de) Verfahren zur herstellung von 2-perfluoroalkyl-3- oxazolin-5-one
KR860002486A (ko) 티아진포스폰산 유도체의 제조방법
KR850005411A (ko) α-메틸-(6-펜옥시)-2- 피콜릴 사이클로프로판 카복실 레이트의 제조방법
DE3682816D1 (de) Verfahren zur herstellung von 2-carboxypyrazin-4-oxiden.
KR890002011A (ko) 5-할로 게노-6-아미노-니코틴산 할라이드. 이의 제조방법 및 용도
ATE59375T1 (de) Verfahren zur herstellung von polyenaldehyden.
DE3577444D1 (de) Stroma-freie haemoglobinloesung, verfahren zu ihrer herstellung und ihre verwendung.
LU88287I2 (fr) Cyproternacetate (Climen)
KR860002451A (ko) 아미드 화합물의 제조방법
ATE157357T1 (de) Verfahren zur herstellung von dihydrofuranonderivaten
KR870000348A (ko) 포스핀산 알루미늄의 아민 첨가 화합물의 제조방법
KR860002473A (ko) 4-메틸-5-티오포름아미디노메틸이미다졸 디하이드로클로라이드의 제조방법
KR830006315A (ko) 티아졸리노트리아진 유도체의 제조방법

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP